Treatment
toxicity, cardiotoxicity
All chemotherapeutic agents are SOC treatments and will be administered as per local policy in terms of patient assessment, chemotherapy dose and frequency. Dose reductions due to toxicity or dihydropyrimidine dehydrogenase (DPYD) mutations will take place according to local hospital guidelines. The use of raltirexed will be accepted in the context of cardiotoxicity.